Effects of Tanreqing injection combined bridgestone on inflammation and immune function of patients with stable COPD

Objective To investigate the effect of Tanreqing injection combined budesonide dermoterol on inflammatory factors, immune function, pulmonary function and arterial blood gas of patients with stable COPD. Methods One hundred and fifty-six patients with stable COPD were randomly divided into two groups, 78 cases in each group. The control group was given budesonide/formoterol, and the observation group was added Tanreqing injection based control group.The inflammatory factors (TNF-α, IL-8 and ICAM-1), immune function (CD3⁺, CD4⁺, CD8⁺and CD4⁺/CD8⁺), pulmonary function (FEV₁, FEV₁% and FEV₁/FEVC), arterial blood gas (PaO₂ and PaCO₂) of two groups were compared. Results After treatment, TNF-α, IL-8 and ICAM-1 levels of two groups were significantly reduced (P<0.05), and observation group was lower than the control group (P<0.05). After treatment, CD3⁺, CD4⁺and CD4⁺/CD8⁺levels of two groups were significantly increased (P<0.05), and observation group was higher than the control group (P<0.05). After treatment, FEV₁, FEV₁% and FEV₁/FVC levels of two groups were significantly increased (P<0.05), and observation group was higher than the control group (P<0.05). After treatment, PaO₂ levels of two groups were significantly increased (P<0.05), and observation group was higher than the control group (P<0.05). After treatment, PaCO₂ levels of two groups were significantly reduced (P<0.05), and observation group was lower than the control group (P<0.05). Conclusion Tanreqing injection combined budesonide dermotam could reduce the inflammatory response, improve the immune function, and improve the lung function and arterial blood gas of patients with COPD.